Cargando…
Long-term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiography
BACKGROUND: Few challenges are faced with the introduction of anti-VEGF agents as a modality of treatment for retinopathy of prematurity. The clinical behavior and time course of regression post injection differ compared to post laser ablation. This study aims to evaluate the long-term peripheral re...
Autores principales: | Al Rasheed, Raghad, Adhi, Mohammad Idrees, Alowedi, Sarah Abdullah, Albdah, Bayan, Aldebasi, Tariq, Hazzazi, Mohammad A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344754/ https://www.ncbi.nlm.nih.gov/pubmed/35918740 http://dx.doi.org/10.1186/s40942-022-00402-3 |
Ejemplares similares
-
Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography
por: Wu, Lei, et al.
Publicado: (2023) -
Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity
por: Jin, Enzhong, et al.
Publicado: (2019) -
Intravitreal Ranibizumab for Aggressive Posterior Retinopathy of Prematurity
por: Li, Xiu-Juan, et al.
Publicado: (2016) -
Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease
por: Menke, Marcel N, et al.
Publicado: (2015) -
Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity
por: Prajapati, Vipul, et al.
Publicado: (2023)